Nivolumab Plus Ipilimumab (NI) Versus Chemotherapy Plus Nivolumab (CN) in Squamous Cell Lung Cancer (SqCLC): The SQUINT Trial

被引：0
|
作者：
Landi, L. [1 ]
Bonanno, L. [2 ]
Delmonte, A. [3 ]
Papi, M. [4 ]
Stati, V. [5 ]
Minotti, V. [6 ]
Bennati, C. [1 ]
D'Inca, F. [7 ]
Migliorino, M. [8 ]
Gori, S. [9 ]
Santo, A. [10 ]
Piantedosi, F. [11 ]
Russo, A. [12 ]
Cappuzzo, F. [1 ]
机构：
[1] Azienda Usl Romagna, Ravenna, Italy
[2] Ist Oncol Veneto, IRCCS, Padua, Italy
[3] IRCCS, Ist Sci Romagnolo Studio & Cura Tumori Irst, Meldola, Italy
[4] Azienda Usl Romagna, Rimini, Italy
[5] IRCCS, European Inst Oncol, Ieo, Div Thorac Oncol, Milan, Italy
[6] Santa Maria Della Misericordia Hosp, Med Oncol, Perugia, Italy
[7] Fdn Ric Traslaz, Rome, Italy
[8] San Camillo Forlanini Hosp, Uosd Pneumol Oncol, Rome, Italy
[9] Osped Sacro Cuore Donna Calabria, IRCCS, Oncol Med, Negrar, Italy
[10] Grp Interdisciplinare Veronese Oncol Polmonare, Uoc Oncol, Verona, Italy
[11] AO Colli Monaldi Cotugno Cto, UOSD Dh Pneumoncol, Naples, Italy
[12] Aoupoliclin P Giaccone, Uoc Oncol Med, Palermo, Italy
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
SqCLC; nivolumab; ipilimumab;
D O I：
10.1016/j.jtho.2019.08.1554
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.04-49
引用
收藏
页码：S727 / S727
页数：1
相关论文
共 50 条
  • [1] Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial
    Landi, L.
    Bonanno, L.
    Delmonte, A.
    Maximilian, P.
    Stati, V.
    Minotti, V.
    Bennati, C.
    D'Inca, F.
    Migliorino, M. R.
    Gori, S.
    Santo, A.
    Piantedosi, F.
    Russo, A.
    Cappuzzo, F.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [2] Nivolumab plus Ipilimumab Vs Platinum-Based CT plus Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
    Delmonte, A.
    Bonanno, L.
    Landi, L.
    Andrikou, K.
    Dal Maso, A.
    Minuti, G.
    Papi, M.
    Metro, G.
    Attili, I.
    Piantedosi, F.
    Pilotto, S.
    Gori, S.
    Rossi, G.
    Buglioni, S.
    Giannarelli, D.
    Cappuzzo, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S351 - S351
  • [3] Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
    Feldman, Hope
    Sepesi, Boris
    Leung, Cheuk H.
    Lin, Heather
    Weissferdt, Annikka
    Pataer, Apar
    William Jr, William N.
    Walsh, Garrett L.
    Rice, David C.
    Roth, Jack A.
    Mehran, Reza J.
    Hofstetter, Wayne L.
    Antonoff, Mara B.
    Rajaram, Ravi
    Gibbons, Don L.
    Lee, J. Jack
    Heymach, John V.
    Vaporciyan, Ara A.
    Swisher, Stephen G.
    Cascone, Tina
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (04):
  • [4] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
    Hindson, Jordan
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (04) : 216 - 216
  • [5] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
    Jordan Hindson
    [J]. Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 216 - 216
  • [6] Discussion to: Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer
    Feldman, Hope
    Bott, Matthew
    Mehran, Reza J.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 167 (04): : 1454 - 1455
  • [7] Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer
    Gil-Sierra, Manuel David
    del Pilar Briceno-Casado, Maria
    Sanchez-Hidalgo, Marina
    [J]. JAMA ONCOLOGY, 2022, 8 (04) : 641 - 642
  • [8] BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer
    Fischer, R. N.
    George, J.
    Schaefer, S.
    Scheel, A.
    Schloesser, H.
    Vehreschild, M.
    von Bergwelt-Baildon, M.
    Nogova, L.
    Abdulla, D. S. Y.
    Michels, S.
    Riedel, R.
    Scheffler, M.
    Brossart, P.
    Engel-Riedel, W.
    Griesinger, F.
    Grohe, C.
    Kambartel, K.
    Kern, J.
    Kopp, H-G
    Neukirchen, J.
    Overbeck, T. R.
    Panse, J.
    Sebastian, M.
    Serke, M.
    Wiewrodt, R.
    Buettner, R.
    Thomas, R.
    Wolf, J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 271
  • [9] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [10] Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer Reply
    Gettinger, Scott
    Redman, Mary W.
    Herbst, Roy S.
    [J]. JAMA ONCOLOGY, 2022, 8 (04) : 642 - 643
12345